Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at StockNews.com

Tandem Diabetes Care (NASDAQ:TNDM) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Friday.

Other analysts have also issued research reports about the company. Stifel Nicolaus upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and upped their target price for the stock from $24.00 to $37.00 in a report on Tuesday, March 26th. Citigroup increased their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $37.00.

Tandem Diabetes Care Trading Down 2.6 %

NASDAQ TNDM opened at $30.93 on Friday. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -8.99 and a beta of 1.12. Tandem Diabetes Care has a 52 week low of $13.82 and a 52 week high of $41.22. The stock’s 50 day moving average price is $29.64 and its two-hundred day moving average price is $24.76. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. As a group, analysts anticipate that Tandem Diabetes Care will post -1.62 earnings per share for the current fiscal year.

Institutional Trading of Tandem Diabetes Care

A number of hedge funds have recently modified their holdings of TNDM. BlackRock Inc. lifted its position in Tandem Diabetes Care by 45.1% during the first quarter. BlackRock Inc. now owns 9,207,560 shares of the medical device company’s stock worth $373,919,000 after acquiring an additional 2,861,120 shares during the last quarter. Vanguard Group Inc. boosted its stake in Tandem Diabetes Care by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company’s stock valued at $207,708,000 after purchasing an additional 18,571 shares during the period. Eminence Capital LP boosted its stake in Tandem Diabetes Care by 76.1% in the 3rd quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock valued at $114,028,000 after purchasing an additional 2,372,458 shares during the period. State Street Corp grew its holdings in Tandem Diabetes Care by 9.2% in the 2nd quarter. State Street Corp now owns 2,257,428 shares of the medical device company’s stock valued at $55,397,000 after buying an additional 190,499 shares in the last quarter. Finally, Invesco Ltd. increased its position in Tandem Diabetes Care by 7.1% during the 1st quarter. Invesco Ltd. now owns 2,080,173 shares of the medical device company’s stock worth $241,904,000 after buying an additional 137,202 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.